Clinical Trial Update: A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of TAK-659 in combination with various agents for advanced non-Hodgkin lymphoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Gemcitabine (Gemcitabine)
• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• TAK-659 (TAK-659)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: TERMINATED | Results posted: 2022-02-18